balloon missed target pop arrows miss failure
Pharma

Syndax ends IPF development after phase 2 disappointment

In topline phase 2 results, Syndax’s Niktimvo did not slow worsening lung function in IPF patients compared to placebo.
Donavyn Coffey Oct 13, 2026 11:25am
Launch

J&J pins high hopes on Icotyde amid strong debut in psoriasis

Oct 13, 2026 11:16am
signing contract

BARDA hands Kaléo $96M contract for chemical threat preparedness

Oct 13, 2026 11:02am
UCB Wear It Out shirts

UCB fashions ‘Wear It Out’ project with empowering t-shirts

Oct 13, 2026 9:00am
RNA Concept 3D Render

Inside the 'first-shoring' philosophy behind ARPA-H RNA project

Oct 13, 2026 8:30am
Skin closeup

Galderma sculpts new narrative around menopausal skin changes

Oct 13, 2026 4:11am
More News

Mirum keeps momentum with ph. 3 win for Livmarli

Oct 12, 2026 11:18am

Bausch + Lomb CEO Brent Saunders hits the exit again

Oct 12, 2026 10:53am

Invenra joins the ADC game with custom card deck

Oct 12, 2026 10:35am

Asahi Kasei makes good on AiCurus buyout with new FDA nod

Oct 12, 2026 10:28am